• Date: 08 June 2026
  • Extracted Insight: The U.S. Food and Drug Administration accepted for review a Biologics License Application (BLA) for AVT16, Alvotech's proposed interchangeable biosimilar to Entyvio, a treatment for inflammatory bowel diseases. If approved, AVT16 could be substituted for Entyvio at pharmacies without prescriber intervention, expanding market access. The FDA acceptance is described as a regulatory milestone for the Iceland‑based biopharmaceutical company. Following the announcement, Alvotech shares jumped 12% in pre‑market trading on Thursday.
  • Relevance: Economic/Market-related
  • Potential Market Impact: Positive / Immediate‑Short‑Term